Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124659074 | 12465907 | 4 | F | 20160808 | 20160614 | 20160811 | EXP | IT-ABBVIE-16P-083-1647538-00 | ABBVIE | CATTANEO D, RIVA A, CLEMENTI E, ET AL. SEVERE HYPERBILIRUBINEMIA IN AN HIV-HCV-COINFECTED PATIENT STARTING THE 3D REGIMEN THAT RESOLVED AFTER TDM-GUIDED ATAZANAVIR DOSE REDUCTION. THERAPEUTIC DURG MONITORING. 2016 JUN;38 (3):285-287. | 53.00 | YR | F | Y | 0.00000 | 20160811 | OT | COUNTRY NOT SPECIFIED | IT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124659074 | 12465907 | 1 | PS | VIEKIRAX | OMBITASVIRPARITAPREVIRRITONAVIR | 1 | Oral | OMBITASVIR 25 MG QD, PARITAPREVIR/RIT 150/100 MG QD | Y | UNKNOWN | 206619 | ||||||||
| 124659074 | 12465907 | 2 | SS | EXVIERA | DASABUVIR | 1 | Oral | Y | UNKNOWN | 206619 | |||||||||
| 124659074 | 12465907 | 3 | SS | RIBAVIRIN. | RIBAVIRIN | 1 | Oral | Y | UNKNOWN | 0 | |||||||||
| 124659074 | 12465907 | 4 | I | ATAZANAVIR | ATAZANAVIR | 1 | Oral | Y | UNKNOWN | 0 | |||||||||
| 124659074 | 12465907 | 5 | I | ATAZANAVIR | ATAZANAVIR | 1 | Oral | Y | UNKNOWN | 0 | |||||||||
| 124659074 | 12465907 | 6 | SS | RALTEGRAVIR. | RALTEGRAVIR | 1 | Oral | Y | UNKNOWN | 0 | 400 | MG | BID | ||||||
| 124659074 | 12465907 | 7 | SS | RITONAVIR. | RITONAVIR | 1 | Oral | Y | UNKNOWN | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124659074 | 12465907 | 1 | Hepatitis C |
| 124659074 | 12465907 | 2 | Hepatitis C |
| 124659074 | 12465907 | 3 | Hepatitis C |
| 124659074 | 12465907 | 4 | HIV infection |
| 124659074 | 12465907 | 6 | HIV infection |
| 124659074 | 12465907 | 7 | HIV infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124659074 | 12465907 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124659074 | 12465907 | Drug interaction | |
| 124659074 | 12465907 | Drug level increased | |
| 124659074 | 12465907 | Hyperbilirubinaemia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124659074 | 12465907 | 1 | 201507 | 0 | ||
| 124659074 | 12465907 | 2 | 201507 | 0 | ||
| 124659074 | 12465907 | 3 | 201507 | 0 | ||
| 124659074 | 12465907 | 4 | 2009 | 201507 | 0 | |
| 124659074 | 12465907 | 6 | 2009 | 0 | ||
| 124659074 | 12465907 | 7 | 2009 | 201507 | 0 |